Bemarituzumab
Generic:
Manufacturer: Amgen · Program:
Apply for assistanceFree to apply. Service from $40/month, payable only when your application is ready to submit.
Eligibility Criteria
Insurance Requirement
See program details
Residency
US residency required
Income Threshold
Up to 500% FPL
Individual Income Limit
$72,900/year
Program Information
Processing Time
1–2 weeks
Delivery Method
shipped to patient
Application Method
Multiple
Indicated for
FGFR2b-positive gastric cancer, gastroesophageal junction cancer
About This Medication
Amgen Support Program Patient Guide: How to Get Bemarituzumab at Low or No Cost
Bemarituzumab is an investigational targeted therapy from Amgen for FGFR2b-positive first-line gastric or gastroesophageal junction (G/GEJ) cancer, showing promising results in improving overall survival when combined with chemotherapy like mFOLFOX6.[1][5] As of March 2026, this drug is not yet FDA-approved, so no established patient assistance program exists—this guide provides general guidance on accessing Amgen support and next steps while you await approval. Contact Amgen directly for the latest information on potential expanded access or future programs.
About Bemarituzumab
Bemarituzumab is a first-in-class investigational monoclonal antibody that targets fibroblast growth factor receptor 2b (FGFR2b), a protein overexpressed in certain gastric and GEJ cancers.[2][7] In the Phase 3 FORTITUDE-101 trial, bemarituzumab plus mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) met its primary endpoint of statistically significant overall survival (OS) improvement compared to chemotherapy alone in patients with FGFR2b overexpression (defined as 2+ or 3+ staining in ≥10% of tumor cells via IHC testing).[1][5][7]
Key trial highlights:
- Conducted across 300 sites in 37 countries with 547 patients.[5]
- Common side effects (>25%) include reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye—ocular events were more frequent and severe with bemarituzumab.[1][5][7]
- Earlier Phase 2 FIGHT trial showed median OS of 19.2 months vs. 13.5 months with chemotherapy alone.[9]
Detailed results are expected at upcoming medical meetings, with another Phase 3 trial (bemarituzumab + chemo + nivolumab) readout anticipated in late 2025.[1][5] If approved, it could become a frontline option for FGFR2b+ tumors, especially HER2-negative cases.[2]
Important note: Since bemarituzumab is investigational, access is currently limited to clinical trials (e.g., NCT05111626 or ongoing studies).[3] Amgen is evaluating FDA paths forward.[8]
Who Qualifies for Assistance?
No specific Amgen patient assistance program (PAP) details are available for bemarituzumab yet, as it's pre-approval. Typical Amgen PAPs (like Amgen Safety Net Foundation or Amgen SupportPlus) target:
- US residents with limited income.
- Patients with commercial insurance, Medicare, or uninsured/underinsured.
- Those meeting Federal Poverty Level (FPL) guidelines (often 400-500% FPL or higher).
Once launched, expect eligibility for patients unable to afford copays, with household income verification. FGFR2b testing (via FDA-approved companion diagnostic) may be required for treatment eligibility.[2]
Income Eligibility Breakdown
Specific thresholds are unavailable pre-approval. Here's a general table based on standard Amgen programs (e.g., for other oncology drugs)—confirm with Amgen post-approval:
| Household Size | Annual Income Limit (e.g., 400-500% FPL) | Notes |
|---|---|---|
| 1 (Individual) | $58,320 - $72,900 | Varies by program; assets may count |
| 2 (Couple) | $78,880 - $98,600 | Includes all household income |
| 3 | $99,440 - $124,300 | Alaska/Hawaii higher |
| 4 | $120,000 - $150,000 | Add ~$20,000 per additional member |
2026 FPL estimates; actuals depend on program. Programs often exclude high assets or certain income types.
Insurance Requirements
Amgen PAPs typically:
- Accept commercial insurance (help with copays up to $5,000-$15,000/year).
- Support Medicare Part D patients (via copay assistance; no coverage for premiums/deductibles).
- Cover uninsured fully if income-qualified.
- Exclude government insurance like Medicaid/VA from free drug (but may bridge gaps).
For bemarituzumab, prior authorization proving FGFR2b+ status will likely be needed.[2][7]
Step-by-Step Application Process
- Verify eligibility: Call Amgen Support at 1-888-4AMGEN (1-888-426-4363) or visit amgen.com/support to check for bemarituzumab-specific programs.[1]
- Get tested: Confirm FGFR2b overexpression via IHC (≥10% tumor cells).[2][7]
- Gather documents: Proof of income (tax returns, W-2s), insurance card, prescription, doctor's statement of medical necessity.
- Apply: Online at amgenassist360.com, by phone, or mail. Doctor/hospital may handle via electronic portal.
- Approval wait: 1-2 weeks typically.
- Receive medication: Shipped to doctor's office or home.
Timeline and Delivery
- Processing: 5-14 business days.[General Amgen standard]
- Delivery: Free shipping via specialty pharmacy to prescriber or patient.
- Supply: 1-3 months initially; auto-refills possible.
Alternatives if Denied or Pre-Approval
- Clinical trials: Enroll via clinicaltrials.gov (e.g., FORTITUDE studies).[3][5]
- Expanded access: Ask Amgen about compassionate use (single-patient IND).[3][8]
- Financial aid: PAN Foundation, CancerCare, or Patient Access Network.
- Biosimilars: None available.[ ]
- Other therapies: Chemotherapy alone (mFOLFOX6), or FGFR inhibitors if applicable.
Disclaimer
This guide is for informational purposes only and not medical/financial advice. Bemarituzumab is investigational—efficacy/safety not established.[1][2] Program details may change; contact Amgen directly. Consult your doctor for personalized options. Word count: 942.
Program information last verified: March 30, 2026
Ready to apply for Bemarituzumab assistance?
ProvisionRX manages the complete application process. Start your application in about 15 minutes.
Need help finding a program?